So had a look over the half year. EBITDA margin decreased to 26.5% (from 33.4%), PDL revenue was strong though so overall they increased revenue by 1% to $64.5M. I am expecting another 20% fall in PDL in 2H16 - however it is important to note that 50% of PDL recoveries are of debt >2yrs old, and 36% of debt recoveries from debt >3yrs old... So a fall of 20% in PDL really equates to a decline of 10% on PDL revenue...
The guidance given of $15.5M - $19.3M, I expect will come in on the lower range - IMO around $16M. With margins being squeezed in the short term I expect EPS to be 12.2c and DPS to be 6.5c, so final of 2.6c... I have an order in @ $1.10 - hopefully this will execute based on negative sentiment.
If not with earnings stabilizing and dividends increasing from 2017 onward, I think fair value right now is ~$1.40.
- Forums
- ASX - By Stock
- CLH
- Bearish chart
Bearish chart, page-61
Featured News
Add CLH (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online